GHRP-2
Overview
A synthetic hexapeptide growth hormone secretagogue that acts on the ghrelin receptor (GHS-R1a) in the hypothalamus and pituitary to stimulate growth hormone release. GHRP-2 is one of the most potent GH-releasing peptides, producing robust GH pulses while also increasing ACTH, cortisol, and prolactin to a modest degree.
Mechanism of Action
It amplifies the natural GH axis and works synergistically with GHRH analogs..
Research Summary & Key Findings
Clinical studies demonstrated dose-dependent GH release with peak levels at 15-30 minutes post-administration. More potent than GHRP-6 with less appetite stimulation. Used clinically in Japan for GH stimulation testing. Research shows sustained IGF-1 elevation and improved body composition parameters.
Clinical Status
GHRP-2 is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
Related Peptides in Hormone
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...
View detailsIpamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...
View detailsSermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...
View detailsTesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...
View detailsFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply GHRP-2.
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.